AR113983A1 - Tratamiento de desórdenes autónomos - Google Patents

Tratamiento de desórdenes autónomos

Info

Publication number
AR113983A1
AR113983A1 ARP180103723A ARP180103723A AR113983A1 AR 113983 A1 AR113983 A1 AR 113983A1 AR P180103723 A ARP180103723 A AR P180103723A AR P180103723 A ARP180103723 A AR P180103723A AR 113983 A1 AR113983 A1 AR 113983A1
Authority
AR
Argentina
Prior art keywords
bont
treatment
disorders
autonomous
dose
Prior art date
Application number
ARP180103723A
Other languages
English (en)
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of AR113983A1 publication Critical patent/AR113983A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente se refiere al tratamiento de trastornos autónomos con una neurotoxina clostridial que comprende un dominio HCC de una BoNT/B, BoNT/D, BoNT/D-C, BoNT/F o BoNT/G, donde la dosis de la neurotoxina clostridial que se administrará al paciente es equivalente o inferior a la dosis de BoNT/A que se usaría para tratar el mismo trastorno autónomo.
ARP180103723A 2017-12-20 2018-12-19 Tratamiento de desórdenes autónomos AR113983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17306840 2017-12-20

Publications (1)

Publication Number Publication Date
AR113983A1 true AR113983A1 (es) 2020-07-08

Family

ID=61027399

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180103723A AR113983A1 (es) 2017-12-20 2018-12-19 Tratamiento de desórdenes autónomos

Country Status (15)

Country Link
US (1) US20200377872A1 (es)
EP (1) EP3727429A1 (es)
JP (3) JP7162059B2 (es)
KR (1) KR20200100625A (es)
CN (1) CN111491659A (es)
AR (1) AR113983A1 (es)
AU (1) AU2018392818A1 (es)
BR (1) BR112020005186A2 (es)
CA (1) CA3083069A1 (es)
EA (1) EA202091527A1 (es)
MA (1) MA51279A (es)
MX (1) MX2020006043A (es)
SG (1) SG11202002876WA (es)
TW (1) TWI810228B (es)
WO (1) WO2019122166A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202001353D0 (en) * 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
AU2021238924A1 (en) * 2020-03-16 2022-08-25 Ipsen Biopharm Limited Modified botulinum neurotoxin for treating limb spasticity
GB202206353D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
WO2024069191A1 (en) * 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
DK2154151T3 (da) 2005-09-19 2011-09-05 Allergan Inc Clostridiumtoksinaktiverbare clostridiumtoksiner
WO2013180799A1 (en) 2012-05-30 2013-12-05 President And Fellows Of Harvard College Engineered botulinum neurotoxin
WO2016154534A1 (en) * 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin
GB201505306D0 (en) 2015-03-27 2015-05-13 Ipsen Biopharm Ltd Chimeric polypeptides
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
AU2017277905B2 (en) * 2016-06-08 2022-04-14 Children's Medical Center Corporation Engineered Botulinum neurotoxins
CN109106957A (zh) * 2018-11-08 2019-01-01 自贡德西玛医疗设备有限公司 一种旋转增效的高温消毒系统

Also Published As

Publication number Publication date
EP3727429A1 (en) 2020-10-28
EA202091527A1 (ru) 2020-09-11
TWI810228B (zh) 2023-08-01
TW202017590A (zh) 2020-05-16
MA51279A (fr) 2021-03-31
SG11202002876WA (en) 2020-07-29
WO2019122166A1 (en) 2019-06-27
CA3083069A1 (en) 2019-06-27
KR20200100625A (ko) 2020-08-26
JP2024059821A (ja) 2024-05-01
US20200377872A1 (en) 2020-12-03
BR112020005186A2 (pt) 2020-09-15
JP2022191409A (ja) 2022-12-27
JP2021504301A (ja) 2021-02-15
JP7445725B2 (ja) 2024-03-07
JP7162059B2 (ja) 2022-10-27
CN111491659A (zh) 2020-08-04
AU2018392818A1 (en) 2020-03-19
MX2020006043A (es) 2020-08-17

Similar Documents

Publication Publication Date Title
AR113983A1 (es) Tratamiento de desórdenes autónomos
CL2018001996A1 (es) Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16)
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
CL2018000853A1 (es) Terapia de combinación de inhibidores de bromodominios y bloqueo de puntos de control inmunitarios para tratar el cáncer.
GT201700246A (es) Métodos y kits para tratar la depresión
CR20160170A (es) Moduladores del factor del complemento b
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
CL2019000190A1 (es) Tratamiento y prevención de los trastornos del sueño.
CL2018003489A1 (es) Composición y método para reducir neutropenia
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
CL2016001794A1 (es) Metodo para administrar tasimelteon a un paciente humano que incluye la administración oral de una dosis efectiva en condiciones de ayuno para tratar un trastorno del ritmo circadiano o un trastorno del sueño, como el trastorno del sueño-vigilia diferente a 24 horas no-24 metodo para acortar el tmax del tasimelteon en un paciente humano que está siendo tratado con tasimelteon.
BR112017010440A2 (pt) administração sublingual de riluzol
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112017010423A2 (pt) formulação sublingual de riluzol
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.
CL2018002734A1 (es) Métodos de tratamiento con vitamina d
CL2019003484A1 (es) Neurotoxina botulínica para el tratamiento de trastornos asociados a hiperactividad de melanocitos y/o exceso de melanina.
CL2020000586A1 (es) Moduladores de la expresión de enac.
CO2019007188A2 (es) Secuelas de lesión pulmonar inducida por baipás cardiopulmonar
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
DOP2022000095A (es) Regímenes de dosificación para usar en el tratamiento de la mielofibrosis y trastornos relacionados con nmp con navitoclax
BR112019024082A2 (pt) Métodos de tratamento para distonia cervical
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
BR112018011663A2 (pt) toxina botulínica para distúrbios primários de humor e afetivos usando neurotransmissor